About Us
PLL THERAPEUTICS
PLL-Therapeutics is a clinical stage biopharmaceutical company, developing an innovative drug and diagnostic for the treatment and follow up of neurodegenerative disease ALS and set up a platform technology for neurologic disease as Parkinson’s and Alzheimer diseases.
PLL-Therapeutics regrouped the patents and R&D on 2 parts
In the diagnostic field by searching the antibodies which are the reflect of neurodegenerative and auto immune disease. 3 patents was setup to cover our Know-how.
In the treatment of neurodegenerative and auto immune disease where our main target is linked to the gut and where the permeability of the intestin is at the origin and too on the chronicity of such disease. Our drug product (DP) is to restore gut permeability and dedicated to slowdown the dedicated disease.
- Success of pre-clinical studies & key learnings
The dysbiosis link to gut microbiota and gut permeability by releasing in the body “components” as chemicals, bacteria represent 90% of the origin of neurodegenerative diseases as ALS in association with genetic effect. To target such side effect at an early stage as PLL-Therapeutics diagnostic kit and therapy will allow this will stop initialization and chronicity and well being of patient.
- Pharmaceutical GMP grade of our drug products allowing us to launch clinical phases in human
- Clinical trials Phase I/II on ALS will be launched in Australia in Q2 2024
- Ethics committee is currently validating our Investigation Medicinal Product Dossier (IMPD)
- Collaborative agreement with ALS patient association in Europe, United states and Australia.
Our technology is based on creating Poly-L-Lysine
Our technology is based on creating Poly-L-Lysine conjugate with active compounds which allow them to increase their shelflife in the body, allow them to go through the Brain Blood barrier (BBB) and to distribute the compound in the cell directly.
Our DP, PLys® (Poly-L-Lysine) is a drug carrier with best-in-class properties conjugating stability, high internalization and no immunogenicity.
STRUCTURE
FORMULATION
INTERNALIZATION (1,3,4)
Poly-L-Lysine Action with Molecular Dynamics by AI – How our DP release our API SCFAs in the Cell
The 70-unit Poly-L-Lysine are soluble in water with more or less local folding according to the conjugate.
When the conjugates are water soluble the nanomolecular object stays in water.
When the conjugates are lipophilic as our SCFAs the nano-object anchors to the biological membranes.
Poly-L-Lysine conjugate with SCFAs
Molecular dynamics simulations allow sampling all intermolecular movements to accurately support Poly-L-Lysine mechanism and localization of action
How is internalized ?
Example of Parkinson origins…looks like ALS origins
- As shown previously with ALS, pro–inflammatory molecules can reach blood circulation through permeabilisation of gut barriers.
- These pro-inflammatory molecules can damaged neuron cells and forms protein aggregates in the brain that’s lead to brain degenerescence.
- Poly-L-Lysine solution target these pro-inflammatory molecules to inhibit the degenerescence process.
- Poly-L-Lysine have a positive impact in each inflammatory/neurodegenerative disease wich this pathway is involed in the origins of the disease.
Scientific Advisory Board
Already launched with key player in NeuroSciences and reglementary field Will be presented shortly
LEADERSHIP
CEO : Dr Jean Pascal Zambaux
Board of Director : Mario Philips | Michel Larroche
New shareholder : Joe Boncore
PLL THERAPEUTICS